16 Mar 2012 07:00

EKF Diagnostics Holdings plc
("EKF" or "the Company")
Â
Trading Update & Notice of Final Results
Â
EKF Diagnostics Holdings plc (AIM: EKF), a worldwide manufacturer of point of care in-vitro diagnostic devices, will announce its final results for the year ended 31 December 2011 on Wednesday, 21 March 2012.
Â
As announced on 19 January 2012, trading in the second half of 2011 was strong with unaudited revenues for the year ended 31 December 2011 of approximately £21.6m, and the Board now believes that adjusted EBITDA will be materially ahead of already revised market expectations.
Â
The management team will be hosting analyst and media briefings on the day. For more information please contact Walbrook PR Ltd.
Â
Enquiries:
EKF Diagnostics Holdings plc | Tel: 029 2071 0570 |
David Evans, Executive Chairman | Mob: 07740 084 452 |
Julian Baines, CEO | Mob: 07788 420 859 |
Collins Stewart Europe Limited | Tel: 020 7523 8000 |
Jamie Adams / Mark Dickenson |
Â
Walbrook PRÂ Limited | Tel: 020 7933 8780 |
Fiona Henson | Mob: 07886 335 992 or fiona.henson@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com |
Â
Â
Â
About EKF Diagnostics Holdings plc
EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US$25.5m).
Â
The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.
Â
In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo_Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.Â
Â
For more information please visit the website: www.ekfdiagnostics.co.uk
Â
Â